A case of central diabetes insipidus associated with cardiac dysfunction

Central diabetes insipidus (CDI) results from a deficiency of arginine vasopressin (AVP) secretion. It is treated by replacement therapy with the synthetic AVP analogue desmopressin. To prevent heart failure in patients with CDI accompanied by cardiac dysfunction, controlling sodium and water intake is essential, using the minimum effective dose of desmopressin.

[1]  Rahul Wadke,et al.  Atrial fibrillation. , 2022, Disease-a-month : DM.

[2]  Y. Oiso,et al.  Clinical review: Treatment of neurohypophyseal diabetes insipidus. , 2013, The Journal of clinical endocrinology and metabolism.

[3]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[4]  T. Sanke,et al.  International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values , 2012, Diabetology International.

[5]  M. Maghnie,et al.  Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. , 2004, Pediatric endocrinology reviews : PER.

[6]  A. Faggiano,et al.  Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance , 2001, Clinical endocrinology.

[7]  F. Marumo,et al.  Urinary excretion of aquaporin-2 in patients with diabetes insipidus. , 1995, The New England journal of medicine.

[8]  L. Share.  Role of vasopressin in cardiovascular regulation. , 1988, Physiological reviews.

[9]  Y. Oiso,et al.  [Clinical assessment of posterior pituitary function by direct measurement of plasma vasopressin levels during hypertonic saline infusion]. , 1986, Nihon Naibunpi Gakkai zasshi.

[10]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[11]  H. Arima,et al.  Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. , 2013, Endocrine journal.

[12]  M. Koo,et al.  PRACTICE GUIDELINES , 2012 .

[13]  O. Vuolteenaho,et al.  BNP as a biomarker in heart disease. , 2005, Advances in clinical chemistry.

[14]  J. G. Verbalis,et al.  Diabetes insipidus. , 1997, Current therapy in endocrinology and metabolism.

[15]  B. Ransil,et al.  Effects of positional changes on inferior vena caval size and dynamics and correlations with right-sided cardiac pressure. , 1987, The American journal of cardiology.

[16]  A. Simon,et al.  Relationship between renin and extracellular fluid volume in normotensive and hypertensive subjects. , 1980, Nephron.